Ardea Biosciences — Intrabiotics Pharmaceuticals — Investor Presentation (February 2003)
19 slides from Ardea Biosciences's investor presentation, Feb 18, 2003
Slide 1: Investor Presentation February 2003
Investor Presentation February 2003
Slide 2: Forward-looking statements
Certain statements in this presentation contain forward-looking information and are subject to risks and uncertainties, such as statements regarding the costs, timing, design and results of product development and clinical trials, estimates of market size for VAP, the ability of IntraBiotics to succ
Slide 3: Rationale for VAP Program
Rationale for VAP Program VAP is the most frequent infection in ICU Substantial morbidity and excess cost No drugs approved to prevent Oral-topical antibiotics known to be effective More than 30 previous trials of conventional antibiotics by others Efficacy significant in meta-analyses and most indi
Slide 4: Leadership in Drug Development
Leadership in Drug Development Ernest Mario, Ph.D., Chairman ex Squibb, Glaxo, Alza Henry Fuchs, M.D., President and CEO Herceptin, Pulmozyme Steve Ketchum, Ph. D., VP, Regulatory Affairs Concerta, Ditropan XL Eric Bjerkholt, SVP and CFO ex JP Morgan
Slide 5: Iseganan: a unique antimicrobial drug
Iseganan: a unique antimicrobial drug Features Analog of porcine neutrophil peptide (protegrin) 17 all-natural amino acids Selected for activity and ease of synthesis Selectively disrupts microbial membranes Broad spectrum of antimicrobial activity Gram-positive and -negative bacteria, yeasts Rapidl
Slide 6: Iseganan is rapidly microbicidal in saliva compared to conventional antibiotics
Minutes 0 4 8 12 16 20 2 3 4 5 6 7 8 9 Vehicle 1 mg/mL Vancomycin 1 mg/mL Ciprofloxacin 1 mg/mL Tobramycin 1 mg/mL Iseganan Log CFU/mL Iseganan is rapidly microbicidal in saliva compared to conventional antibiotics In-vitro experiments conducted by IntraBiotics.
Slide 7: Aspiration of oral bacteria causes VAP
Aspiration into the lungs "Pneumonia" Bacteria from oral cavity Aspiration of oral bacteria causes VAP Mechanical ventilation: patient cannot breathe Difficulty clearing secretions Oral bacteria aspirated Lungs ordinarily sterile Pneumonia ensues Most common ICU infection (approx 20% of intubated pa
Slide 8: VAP is associated with high morbidity and cost
VAP is associated with high morbidity and cost Epidemiology and outcomes of ventilator associated pneumonia in a large US database. Rello, Ollendorf, Oster, Vera-Llonch, Bellm, Redman and Kolleff. (2002) Chest, 122:2115-21. Ventilator Intensive Care Hospital VAP Present 14.3 11.7 25.5 VAP Absent 4.7
Slide 9: Prior Clinical Trials: 65% Average Reduction in VAP from Antibiotic Prophylaxis
Prior Clinical Trials: 65% Average Reduction in VAP from Antibiotic Prophylaxis D'Amico R, Torri V, Tinazzi A, and Liberati A. Effectiveness of antibiotic prophylaxis in critically ill adult patients: systematic review of randomised controlled trials. 1998. BMJ, 316: 1275-85.
Slide 10: Reducing VAP: Additional Health Benefits
Reducing VAP: Additional Health Benefits Antibiotics (n=87) Control (n=78) Statistics Incidence of VAP 10% 31% P=0.001 Courses of systemic antibiotics in ICU 0.95 1.30 P=0.02 Infections 36% 51% P=0.04 ICU Mortality 29% 35% NS Prevention of ventilator-associated pneumonia by oral decontamination: a p
Slide 11: Expert Consensus on Efficacy of VAP Prevention Using Antibiotics
Expert Consensus on Efficacy of VAP Prevention Using Antibiotics "The data supporting a significant reduction in risk of VAP ... using topical and short-term intravenous antibiotics are strong... What remains to be determined is the long-term effect on antibiotic resistance patterns." Making Health
Slide 12: Low Propensity to Resistance Transfer
Low Propensity to Resistance Transfer 0 1 2 3 4 5 6 7 8 9 0 100 200 300 400 500 600 700 IB-367 Norfloxacin MIC (µg/mL) Pseudomonas does not develop resistance to iseganan* * Based on in-vitro experiments conducted by IntraBiotics.
Slide 13: Early safety and antimicrobial efficacy promising
Early safety and antimicrobial efficacy promising 0 0.5 2 4 6 8 12 9 mg solution 3.87 1.45 2.18 2.9 3.32 3.23 3.24 placebo 3.7 3.82 3.86 4.2 3.92 4.1 3.85 Iseganan Phase I & II studies 40 patients 2-3 log reduction in CFU count from oral samples 4-8 hour duration of effect No significant adverse eve
Slide 14: Phase II/III to Evaluate Efficacy
Phase II/III to Evaluate Efficacy Expert input: efficacy trial(s) logical next step Proof of principle is established Iseganan has ideal properties for antibiotic prophylaxis Enrollment criteria will give enriched patient pool Known high risk groups to assure VAP frequent in control group Expected t
Slide 15: Opportunity for Iseganan
Opportunity for Iseganan Patient Population # Patients (1998) Economic Benefit (1) Opportunity (millions) (2) Patients on MV ? 48 hours 400,000* $2,000- $4,000 $800 - $1,600 High value indication Prevent poor health outcomes if no prevention administered Reduction in utilization of ancillary resourc
Slide 16: VAP Program Time and Costs
VAP Program Time and Costs Timeline First patient in expected Q2 '03 Data expected Q2 '04 Available financial resources Cash/short-term investment balance 12.02 $13.3MM Raise up to $3.5MM subject to shareholder approval Cash expected to last until H2 2004 $2-3 million per quarter until trial unblind
Slide 17: Summary Terms of Proposed Financing
Summary Terms of Proposed Financing Up to $3.5 million Series A Convertible Preferred Stock Priced at 8% discount to the lower of the 5-day average closing price prior to signing the purchase agreement and the 5-day average closing price prior to the issue date 8% paid-in-common dividend 50% warrant
Slide 18: Additional Issues Requiring Shareholder Approval
Additional Issues Requiring Shareholder Approval Reverse split (1:8 to 1:12 range) Increase in authorized shares from 70MM to 100MM Increase in options available for grant under stock option plan by 1.9MM options
Slide 19: Additional Information about the Transactions and Where to Find It
Additional Information about the Transactions and Where to Find It On February 12, 2003 IntraBiotics filed a preliminary proxy statement with the Securities and Exchange Commission relating to a solicitation of proxies from its stockholders in connection with a special meeting of stockholders of Int
Intrabiotics Pharmaceuticals — Investor Presentation (February 2003) on 6ix